TechNation: Alooma Acquired by Google Cloud for an Estimated $150 Million

JVP raises $220 million for eighth tech fund ■ BiomX raises $32 million for acne, irritable bowel treatments

FILE Photo: Palo Alto Networks in California.
Smith Collection / Gado / Getty

JVP raises $220 million for eighth tech fund

Israeli venture capital firm Jerusalem Venture Partners said on Wednesday it closed a new fund with investment commitments of $220 million from investors from the United States, Europe and Asia, including sovereign wealth funds, corporations, insurance companies and university endowments. JVP had originally planned to raise just $160 million but increased the takings amid huge demand from investors. The JVP VIII fund is investing in early-to-mid-stage startups in computer vision, cybersecurity, artificial intelligence and big data. Several of the companies are U.S.-Israeli or European-Israeli, JVP founder and Executive Chairman Erel Margalit said. “It’s a sign that the next generation of Israeli companies doesn’t just want to be bought by multinationals but wants to create its own international business leadership,” Margalit said. JVP, which has investment hubs in Jerusalem, the southern Israeli city of Beersheba and a new one in New York, has raised $1.4 billion to date in nine funds. (Irad Atzmon Schmayer)

Alooma acquired by Google Cloud for an estimated $150 million

Just hours after Palo Alto Networks said it was acquiring Israeli startup Demisto, Google Cloud revealed on Tuesday that it was buying Israel’s Alooma. The U.S. company didn’t reveal the price it was paying for Alooma, which helps corporate customers migrate their data to the cloud, but sources estimated it is $150 million. “The addition of Alooma … is a natural fit that allows us to offer customers a streamlined, automated migration experience to Google Cloud, and give them access to our full range of database services,” Google executives Amit Ganesh and Dominic Preuss said in a blog post. Alooma was formed in 2013 by Yoni Broyde, Yair Weinberger and Rami Amar, three alumni of the Israel Defense Forces’ elite Talpiot academic program. The company reported raising $15 million in 2016 from the U.S. venture funds Sequoia Capital and Lightspeed Venture Partners and is believed to have raised another $5 million from Israel’s Vintage Venture Partners. (Ruti Levy)

BiomX raises $32 million for acne, irritable bowel treatments

Israeli biopharma firm BiomX said on Wednesday that it raised $32 million in a private funding round that will primarily be used to advance the company’s drug candidates for the treatment of acne and inflammatory bowel disease. The round was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC Inc, Takeda Ventures, 8VC, MiraeAsset, Seventure Partners’ Health for Life Capital I and SBI Japan-Israel Innovation Fund. They were joined by additional European investors and new investors, BiomX said. “The new funding will enable us to transition BiomX to a clinical stage company as our lead programs in acne and IBD — both novel phage therapeutics targeting harmful bacteria in the microbiome — enter the clinic,” said BiomX CEO Jonathan Solomon. BiomX will also continue to advance its liver disease and colorectal cancer programs by identifying key bacteria driving these diseases and developing phage cocktails against them, he added. (Reuters)